SAREPTA THERAPEUTICS, INC. Income Taxes Paid
SAREPTA THERAPEUTICS, INC. (SRPT) reported Income Taxes Paid of $9.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaidNet · last filed 2026-08-05
- SAREPTA THERAPEUTICS, INC. income taxes paid, net for the quarter ending 2026-06-30 was $7.74M, a 59.79% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. income taxes paid, net for the quarter ending 2026-03-31 was $1.73M, a 106.95% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. income taxes paid, net for the quarter ending 2025-12-31 was $16.38M, a 49.30% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. income taxes paid, net for the quarter ending 2025-09-30 was $1.16M, a 68.10% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. income taxes paid, net for fiscal 2025 was $37.63M, a 66.61% increase from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. income taxes paid, net for fiscal 2024 was $22.59M, a 49.77% increase from fiscal 2023.
- SAREPTA THERAPEUTICS, INC. income taxes paid, net for fiscal 2023 was $15.08M, a 789.73% increase from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. income taxes paid, net for fiscal 2022 was $1.70M, a 190.74% increase from fiscal 2021.
| Period end | Income Taxes Paid, Net 3 month | Income Taxes Paid, Net 6 month | Income Taxes Paid, Net 9 month | Income Taxes Paid, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $9.47M 10-Q · filed 2026-08-05 | $25.86M derived: sum of 3 quarters · filed 2026-08-05 | $27.01M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.73M 10-Q · filed 2026-05-06 | $18.11M derived: sum of 2 quarters · filed 2026-05-06 | $19.27M derived: sum of 3 quarters · filed 2026-05-06 | $38.52M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $16.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $17.54M derived: sum of 2 quarters · filed 2026-03-02 | $36.80M derived: sum of 3 quarters · filed 2026-08-05 | $37.63M 10-K · filed 2026-03-02 |
| 2025-09-30 | $1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $20.41M derived: sum of 2 quarters · filed 2026-08-05 | $21.25M 10-Q · filed 2025-11-06 | $32.22M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $19.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $20.09M 10-Q · filed 2026-08-05 | $31.07M derived: sum of 3 quarters · filed 2026-08-05 | $34.69M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $835.00K 10-Q · filed 2026-05-06 | $11.81M derived: sum of 2 quarters · filed 2026-05-06 | $15.43M derived: sum of 3 quarters · filed 2026-05-06 | $22.51M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $10.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $14.60M derived: sum of 2 quarters · filed 2026-03-02 | $21.68M derived: sum of 3 quarters · filed 2026-03-02 | $22.59M 10-K · filed 2026-03-02 |
| 2024-09-30 | $3.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $10.71M derived: sum of 2 quarters · filed 2025-11-06 | $11.61M 10-Q · filed 2025-11-06 | $17.13M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $7.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $7.99M 10-Q · filed 2025-08-06 | $13.50M derived: sum of 3 quarters · filed 2026-03-02 | $17.08M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $909.00K 10-Q · filed 2025-05-06 | $6.42M derived: sum of 2 quarters · filed 2026-03-02 | $10.00M derived: sum of 3 quarters · filed 2026-03-02 | $15.46M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $5.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $9.09M derived: sum of 2 quarters · filed 2026-03-02 | $14.55M derived: sum of 3 quarters · filed 2026-03-02 | $15.08M 10-K · filed 2026-03-02 |
| 2023-09-30 | $3.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $9.03M derived: sum of 2 quarters · filed 2024-11-06 | $9.57M 10-Q · filed 2024-11-06 | $9.91M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $5.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $5.99M 10-Q · filed 2024-08-07 | $6.33M derived: sum of 3 quarters · filed 2025-02-28 | |
| 2023-03-31 | $535.00K 10-Q · filed 2024-05-01 | $874.00K derived: sum of 2 quarters · filed 2025-02-28 | ||
| 2022-12-31 | $339.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $1.70M 10-K · filed 2025-02-28 | ||
| 2022-09-30 | $1.36M 10-Q · filed 2023-11-01 | |||
| 2021-12-31 | $583.00K 10-K · filed 2024-02-28 | |||
| 2020-12-31 | $2.51M 10-K · filed 2023-02-28 | |||
| 2019-12-31 | $933.00K 10-K · filed 2022-03-01 | |||
| 2018-12-31 | $1.55M 10-K · filed 2021-03-01 | |||
| 2017-12-31 | $5.34M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |